• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

家兔体内标准肝素消失的可饱和机制的证据。

Evidence for a saturable mechanism of disappearance of standard heparin in rabbits.

作者信息

Boneu B, Caranobe C, Gabaig A M, Dupouy D, Sie P, Buchanan M R, Hirsh J

出版信息

Thromb Res. 1987 Jun 15;46(6):835-44. doi: 10.1016/0049-3848(87)90075-2.

DOI:10.1016/0049-3848(87)90075-2
PMID:3629550
Abstract

This work demonstrates that after bolus intravenous injection standard heparin (SH) disappearance results from the combination of a saturable and a non saturable mechanism. Pharmacokinetics and pharmacodynamics of SH were studied by measuring the disappearance of increasing doses (5 - 500 anti-factor Xa U/kg) of 125I-heparin and of its biological effects. CPM curves allowed to determine the half lives of heparin according to the dose injected. The half lives were clearly dose dependent and reached a plateau over 100 anti-factor Xa U/kg. The complex curve which describes the amount of heparin cleared per time unit after any given dose has been resolved into its two components reflecting a saturable and a non saturable mechanism of disappearance. For the doses less than 100 anti-factor Xa U/kg the saturable mechanism was preeminent and the anti-factor Xa activity disappearance followed an exponential pattern; for the doses less than 100 anti-factor Xa U/kg the contribution of the non saturable mechanism becomes more important and the anti-factor Xa activity disappearance followed a concave-convex pattern. Further experiments showed that the heparin half life shortened as the circulating anti-factor Xa activity decreased; this phenomenon may explain the concave-convex pattern of the curve of the anticoagulant effect observed after injection of large doses of SH.

摘要

这项研究表明,静脉推注标准肝素(SH)后,其消失是由可饱和和不可饱和机制共同作用的结果。通过测量递增剂量(5 - 500抗Xa因子单位/千克)的125I-肝素及其生物学效应的消失情况,研究了SH的药代动力学和药效学。计数率曲线有助于根据注射剂量确定肝素的半衰期。半衰期明显依赖于剂量,在超过100抗Xa因子单位/千克时达到平台期。描述在任何给定剂量后单位时间内清除的肝素量的复杂曲线已分解为反映可饱和和不可饱和消失机制的两个组成部分。对于小于100抗Xa因子单位/千克的剂量,可饱和机制占主导,抗Xa因子活性的消失呈指数模式;对于大于100抗Xa因子单位/千克的剂量,不可饱和机制的作用变得更加重要,抗Xa因子活性的消失呈凹凸模式。进一步的实验表明,随着循环抗Xa因子活性降低,肝素半衰期缩短;这种现象可能解释了注射大剂量SH后观察到的抗凝效应曲线的凹凸模式。

相似文献

1
Evidence for a saturable mechanism of disappearance of standard heparin in rabbits.家兔体内标准肝素消失的可饱和机制的证据。
Thromb Res. 1987 Jun 15;46(6):835-44. doi: 10.1016/0049-3848(87)90075-2.
2
The disappearance of a low molecular weight heparin fraction (CY 216) differs from standard heparin in rabbits.低分子量肝素组分(CY 216)在兔体内的消除情况与标准肝素不同。
Thromb Res. 1987 Jun 15;46(6):845-53. doi: 10.1016/0049-3848(87)90076-4.
3
Pharmacokinetics of heparin and related polysaccharides.肝素及相关多糖的药代动力学
Ann N Y Acad Sci. 1989;556:282-91. doi: 10.1111/j.1749-6632.1989.tb22510.x.
4
Pharmacokinetics of heparin and low molecular weight heparin.
Baillieres Clin Haematol. 1990 Jul;3(3):531-44. doi: 10.1016/s0950-3536(05)80017-4.
5
Kinetics of intravenously administered heparin in normal humans.正常人静脉注射肝素的动力学
Blood. 1982 Dec;60(6):1251-8.
6
Heparin fractions with high and low affinities to antithrombin III are cleared at different rates.
Thromb Res. 1986 Sep 15;43(6):635-41. doi: 10.1016/0049-3848(86)90100-3.
7
Pharmacokinetic studies of standard heparin and low molecular weight heparin in patients with chronic renal failure.慢性肾衰竭患者中标准肝素和低分子量肝素的药代动力学研究。
Haemostasis. 1986;16(2):147-51. doi: 10.1159/000215284.
8
Pharmacodynamics of CY 216 in healthy volunteers: inter-individual variations.CY 216在健康志愿者中的药效学:个体间差异。
Fundam Clin Pharmacol. 1990;4(1):17-23. doi: 10.1111/j.1472-8206.1990.tb01013.x.
9
Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit.普通肝素与CY 216:兔静脉注射和皮下注射后抗Xa因子和抗IIa因子作用的药代动力学及生物利用度
Thromb Haemost. 1989 Jun 30;61(3):348-53.
10
Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers.静脉注射和皮下注射替扎肝素及肝素在健康志愿者中的药效学
Am J Health Syst Pharm. 2001 Sep 1;58(17):1614-21. doi: 10.1093/ajhp/58.17.1614.

引用本文的文献

1
Heavy Heparin: A Stable Isotope-Enriched, Chemoenzymatically-Synthesized, Poly-Component Drug.重肝素:一种稳定同位素标记、化学酶合成、多组分药物。
Angew Chem Int Ed Engl. 2019 Apr 23;58(18):5962-5966. doi: 10.1002/anie.201900768. Epub 2019 Apr 1.
2
The Role of Tinzaparin in Oncology.亭扎肝素在肿瘤学中的作用。
Clin Appl Thromb Hemost. 2018 Jul;24(5):697-707. doi: 10.1177/1076029617729215. Epub 2017 Oct 31.
3
Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?
亭扎肝素和其他低分子肝素:有何证据表明它们对肾脏清除率的依赖存在差异?
Exp Hematol Oncol. 2013 Aug 8;2:21. doi: 10.1186/2162-3619-2-21. eCollection 2013.
4
Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.普通肝素和低分子量肝素的药物治疗学方面
Drugs. 1990 Oct;40(4):498-530. doi: 10.2165/00003495-199040040-00003.
5
Heparin pharmacokinetics and pharmacodynamics.肝素的药代动力学和药效学。
Clin Pharmacokinet. 1992 May;22(5):359-74. doi: 10.2165/00003088-199222050-00003.
6
Hepatic uptake of a modified low molecular weight heparin in rats.大鼠对一种改良低分子量肝素的肝脏摄取。
J Clin Invest. 1992 Nov;90(5):2110-6. doi: 10.1172/JCI116095.
7
Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders.那屈肝素钙。其药理学及在预防和治疗血栓栓塞性疾病中的临床应用综述。
Drugs. 1992 Nov;44(5):858-88. doi: 10.2165/00003495-199244050-00010.